Impact of biological and non-biological treatment on hematological indices in patients with ankylosing spondylitis and psoriatic arthritis

Egyptian Rheumatology and Rehabilitation

Table 7 Correlation between the WBCs, RBCs and Platelets indices with duration of biologic therapy

PSA	Duration biologics (months)
PSA	r	P value
WBCS	0.337	0.033*
Neutrophils	0.313	0.049*
Lymphocytes	0.265	0.098
HCT	− 0.127	0.436
RBCs	− 0.034	0.833
Hb	− 0.112	0.490
MCV	− 0.028	0.865
MCH	0.105	0.520
RDW%	0.163	0.316
PLT	0.134	0.411
MPV/fl	− 0.155	0.341
PDW	− 0.072	0.658
Hb/PLT ratio	− 0.121	0.457
RDW%/PLT ratio	− 0.088	0.591
RBCs/PLT ratio	− 0.068	0.676
Hb/RDW% ratio	− 0.151	0.351
Neutrophil/lymphocyte ratio	0.128	0.430
PLT/lymphocyte ratio	− 0.105	0.520

PsA psoriatic arthritis, DD disease duration, WBCs white blood cells, HCT hematocrit, RBCs red blood cells, HB hemoglobin, MCV mean corpuscular volume, MCH mean corpuscular hemoglobin, RDW red cell distribution width, PLT platelet, MPV mean platelet volume, PDW platelet distribution width, SD standard deviation. Level of significance: P ≤ 0.05: significant, P < 0.005: highly significant